HRP20241453T1 - Psma ligandi za snimanje i endoradioterapiju - Google Patents
Psma ligandi za snimanje i endoradioterapiju Download PDFInfo
- Publication number
- HRP20241453T1 HRP20241453T1 HRP20241453TT HRP20241453T HRP20241453T1 HR P20241453 T1 HRP20241453 T1 HR P20241453T1 HR P20241453T T HRP20241453T T HR P20241453TT HR P20241453 T HRP20241453 T HR P20241453T HR P20241453 T1 HRP20241453 T1 HR P20241453T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- bond
- image
- pharmaceutical composition
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nuclear Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (21)
1. Farmaceutski pripravak, naznačeno time, što sadrži:
(a) spoj formule (1) ili
(b) njegovu farmaceutski prihvatljivu sol,
[image]
pri čemu:
m je cijeli broj od 2 do 6;
n je cijeli broj od 2 do 6;
R1L je CH2, NH ili O;
R2L je C ili P(OH);
R3L je CH2, NH ili O;
X1 je odabran između amidne veze, eterske veze, tioeterske veze, esterske veze, tioesterske veze, urea mosta i aminske veze;
L1 je dvovalentna vezna skupina sa strukturom odabranom između oligoamida, oligoetera, oligotioetera, oligoestera, oligotioestera, oligouree, oligo(eter-amida), oligo(tioeter-amida), oligo(esteramida) , oligo(tioester-amid), oligo(urea-amid), oligo(eter-tioeter), oligo(eter-ester), oligo(eter-tioester), oligo(eter-urea), oligo (tioeter-ester), oligo(tioeter-tioester), oligo(tioeter- urea), oligo(ester-tioester), oligo(ester-urea) i oligo(tioester-urea), koja vezna grupa može nositi grupni EDS;
X2 se bira između amidne veze, eterske veze, tioeterske veze, esterske veze, tioesterske veze, urea mosta i aminske veze;
R2 je izborno supstituirana arilna skupina ili izborno supstituirana aralkilna skupina, koja arilna skupina ili aralkilna skupina može biti supstituirana na svom aromatskom prstenu s jednim ili više supstituenata odabranih između halogena i -OH;
R3 je izborno supstituirana arilna skupina ili izborno supstituirana aralkilna skupina, koja arilna skupina ili aralkilna skupina može biti supstituirana na svom aromatskom prstenu s jednim ili više supstituenata odabranih između halogena
i -OH;
r je 0 ili 1;
p je 0 ili 1;
q je 0 ili 1;
R4 se bira između izborno supstituirane arilne skupine i skupine EDS, koja arilna skupina može biti supstituirana na svom aromatičnom prstenu s jednim ili više supstituenata odabranih između halogena, -OH i -NH2;
X3 se bira između amidne veze, eterske veze, tioeterske veze, esterske veze, tioesterske veze, urea mosta, aminske veze i skupine formule
[image]
pri čemu označena veza na karbonilnoj skupini veže X3 za RM, a druga označena veza veže X3 za ostatak spoja formule (I);
RM je markerska skupina koja sadrži kelirajuću skupinu koja izborno sadrži kelirani neradioaktivni ili radioaktivni kation;
i pri čemu je skupina EDS barem jednom sadržana u spoju formule (I) i ima strukturu odabranu između (E-1A), (E-1B), (E-2A) i (E-2B):
[image]
[image]
pri čemu
[image]
označava vezu koja veže skupinu EDS, na ostatak spoja formule (I);
s je 1, 2 ili 3, poželjno 1 ili 2, a još poželjnije 1;
t je 1, 2 ili 3, poželjno 1 ili 2, a još poželjnije 2;
R5A je, neovisno za svaku pojavu za s > 1, supstituent za povlačenje elektrona, koji je poželjno odabran između -NO2 i -COOH, a koji je poželjnije -COOH, i pri čemu veza između R5A i fenilnog prstena pokazuje da s skupine R5A zamjenjuju s atome vodika na bilo kojem položaju na fenilnom prstenu;
R5B je, neovisno za svaku pojavu za s > 1, supstituent koji nosi usamljeni par elektrona na atomu izravno vezan na fenilni prsten prikazan u formuli (E-1B), a koji je supstituent poželjno odabran između -OH i -NH2, i što je poželjnije -NH2, i pri čemu veza između R5B i fenilnog prstena pokazuje da s skupine R5B zamjenjuju s atome vodika na bilo kojem položaju na fenilnom prstenu;
R6A je, neovisno za svaku pojavu za t > 1, supstituent za povlačenje elektrona, koji je poželjno odabran između -NO2 i -COOH, a koji je poželjnije -COOH, i pri čemu veza između R6A i fenilnog prstena pokazuje da t skupine R6A zamjenjuju t atome vodika na bilo kojem položaju na fenilnom prstenu; i
R6B je, neovisno za svaku pojavu za t > 1, supstituent koji nosi usamljeni par elektrona na atomu izravno vezan na fenilni prsten prikazan u formuli (E-1B), a koji je supstituent poželjno odabran između -OH i -NH2, a koji je poželjnije -OH, i pri čemu veza između R6B i fenilnog prstena ukazuje da t skupine R6B zamjenjuju t atome vodika na bilo kojem položaju na fenilnom prstenu; i
b) farmaceutski prihvatljiv nosač, pomoćna tvar i/ili razrjeđivač
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačeno time, da m je 2, n je 2 ili 4, R1L je NH, R2L je C, a R3L je NH.
3. Farmaceutski pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, što je L1 dvovalentna vezna skupina sa strukturom odabranom od oligoamida koji sadrži ukupno 1 do 5, poželjnije ukupno 1 do 3, a najpoželjnije ukupno 1 ili 2 amidne veze unutar svoje okosnice i oligo(ester- amid) koji sadrži ukupno 2 do 5, poželjnije ukupno 2 do 3, a najpoželjnije ukupno 2 amidne i esterske veze unutar svoje okosnice, koje povezujuća skupina može nositi grupni EDS.
4. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time, što dio -X2-L1-X1- u formuli (I) ima strukturu odabranu od:
*-C(O)-NH-R7-NH-C(O)-R8-C(O)-NH- (L-1),
*-C(O)-NH-R9A-NH-C(O)-R10A-C(O)-NH-R11A-NH-C(O)- (L-2A),
i
*-C(O)-NH-R9B-C(O)-NH-R10B-C(O)-NH-R11B-NH-C(O)- (L-2B);
pri čemu je amidna veza označena sa * vezana na atom ugljika koji nosi R2 u formuli (I), i gdje su
R7, R8, R9A, R9B, R11A i R11B neovisno odabrani između po izboru supstituiranog C2 do C10 alkandiila, od kojih svaka alkandiilna skupina može biti supstituirana s jednim ili više supstituenata neovisno odabranih između -OH, -OCH3, -COOH, -COOCH3, - NH2, -NHC(NH)NH2, i grupa EDS, i C10 arenediil, od kojih alkandiil i arenediil grupa mogu biti supstituirane s jednim ili više supstituenata neovisno odabranih između -OH, -OCH3, -COOH, -COOCH3, -NH2, -NHC(NH)NH2, i grupa EDS.
5. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačeno time, što dio -X2-L1-X1- ima strukturu odabranu od:
*-C(O)-NH-CH(COOH)-R12-NH-C(O)-R13-C(O)-NH-(L-3),
*-C(O)-NH-CH(COOH)-R14-NH-C(O)-R15-C(O)-NH-R16-CH(COOH)-NH-C(O)-(L-4 ),
i
*-C(O)-NH-CH(COOH)-R17-C(O)-NH-R18-C(O)-NH-R19-CH(COOH)-NH-C(O)-(L-5 );
pri čemu je veza koja je označena sa * vezana na atom ugljika koji nosi R2 u formuli (I),
R12 i R14 su neovisno odabrani između ravnog C2 do C6 alkandiila,
R13 je ravni C2 do C10 alkandiil,
R15 i R16 su neovisno odabrani između ravnog C2 do C6 alkandiila,
i pri čemu svaki od R13 i R15 može nositi jednu skupinu EDS kao supstituent,
R17 je ravni C2 do C6 alkandiil,
R18 je fenilenska skupina, i
R19 je ravni C2 do C6 alkandiil.
6. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačeno time, što je R2 je po izboru supstituirana aralkilna skupina odabrana od po izboru supstituiranog -CH2-fenila i po izboru supstituiranog -CH2-naftila, pri čemu su fenil i naftilna skupina po izboru supstituirani s odabranim supstituentom od halogena, poželjno I i -OH.
7. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačeno time, gdje je R3 po izboru supstituirana aralkilna skupina, po izboru odabrana od supstituiranog -CH2-fenila i po izboru supstituiranog -CH2-naftila, pri čemu su fenil i naftilna skupina po izboru supstituirane s odabranim supstituentom od halogena i -OH.
8. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačeno time, gdje je r 1, i pri čemu je R4 odabran između izborno supstituiranog fenila, izborno supstituiranog naftila i grupe EDS, pri čemu su fenilna skupina i naftilna skupina po izboru supstituirane sa supstituentom odabranim od halogena, -OH i -NH2.
9. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačeno time, što je X3 amidna veza ili skupina formule
[image]
pri čemu označena veza na karbonilnoj skupini veže X3 za RM, a druga označena veza veže X3 za ostatak molekule.
10. Farmaceutski pripravak u skladu bilo kojim od patentnih zahtjeva 1 do 9, naznačeno time, da RM je kelatna skupina koja izborno sadrži kelirani neradioaktivni ili radioaktivni kation.
11. Farmaceutski pripravak u skladu s bilo kojim patentnim zahtjevom od 1 do 10, naznačeno time, da spoj formule (I) ili sadrži jednu skupinu EDS koju nosi vezna skupina L1 ili sadrži dvije skupine EDS, od kojih je jedna predstavljena s R4, a druga se nosi s L1.
12. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačeno time, što sadrži skupinu EDS koja ima formulu (E-2A):
[image]
pri čemu
[image]
označava vezu koja veže skupinu EDS na ostatak spoja formule (I); i
t je 1 ili 2, a R6A se bira između -NO2 i -COOH.
13. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačeno time, što navedeni spoj ili sol imaju jednu od sljedećih formula:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
14. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačeno time, što ima strukturnu formulu kako slijedi:
[image]
ili njegova sol.
15. Farmaceutski pripravak u skladu s patentnih zahtjevom 1, naznačeno time, što ima strukturnu formulu kako slijedi:
[image]
ili njegova sol.
16. Farmaceutski pripravak u skladu s patentnih zahtjevom 1, naznačeno time, što ima strukturnu formulu kako slijedi:
[image]
ili njegova sol.
17. Farmaceutski pripravak u skladu s patentnih zahtjevom 1, naznačeno time, što ima strukturnu formulu kako slijedi:
[image]
ili njegova sol.
18. Farmaceutski pripravak u skladu s bilo kojim patentnim zahtjevom od 1 do 17, naznačeno time, što se koristi u medicini.
19. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 18, naznačeno time, što se koristi kao lijek u radioterapiji kod bolesti povezane s prekomjernom ekspresijom membranskog antigena specifičnog za prostatu (PSMA).
20. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 17, naznačeno time, što je za uporabu u liječenju raka.
21. Farmaceutski pripravak u skladu s patentnim zahtjevom 20, naznačeno time, što je rak - rak prostate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17206510 | 2017-12-11 | ||
| EP21218180.4A EP4008359B1 (en) | 2017-12-11 | 2018-12-11 | Psma ligands for imaging and endoradiotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241453T1 true HRP20241453T1 (hr) | 2024-12-20 |
Family
ID=60654872
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220764TT HRP20220764T1 (hr) | 2017-12-11 | 2018-12-11 | Psma ligandi za snimanje i endoradioterapiju |
| HRP20241453TT HRP20241453T1 (hr) | 2017-12-11 | 2018-12-11 | Psma ligandi za snimanje i endoradioterapiju |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220764TT HRP20220764T1 (hr) | 2017-12-11 | 2018-12-11 | Psma ligandi za snimanje i endoradioterapiju |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US11497819B2 (hr) |
| EP (3) | EP3723815B1 (hr) |
| JP (3) | JP7317375B2 (hr) |
| KR (1) | KR102815791B1 (hr) |
| CN (2) | CN116617421A (hr) |
| AU (2) | AU2018382479B2 (hr) |
| BR (1) | BR112020011727A2 (hr) |
| CA (1) | CA3078104A1 (hr) |
| CL (1) | CL2020001542A1 (hr) |
| CR (1) | CR20200241A (hr) |
| CU (1) | CU24677B1 (hr) |
| CY (1) | CY1125376T1 (hr) |
| DK (2) | DK4008359T3 (hr) |
| EC (1) | ECSP20029142A (hr) |
| ES (2) | ES2997266T3 (hr) |
| FI (1) | FI4008359T3 (hr) |
| HR (2) | HRP20220764T1 (hr) |
| HU (2) | HUE069034T2 (hr) |
| IL (3) | IL319022A (hr) |
| JO (1) | JOP20200135A1 (hr) |
| LT (2) | LT3723815T (hr) |
| MX (2) | MX2020005430A (hr) |
| NZ (1) | NZ763033A (hr) |
| PE (1) | PE20210456A1 (hr) |
| PL (1) | PL3723815T3 (hr) |
| PT (2) | PT3723815T (hr) |
| RS (2) | RS63279B1 (hr) |
| SG (1) | SG11202002965WA (hr) |
| SI (2) | SI4008359T1 (hr) |
| SM (1) | SMT202400439T1 (hr) |
| TN (1) | TN2020000072A1 (hr) |
| UA (1) | UA126413C2 (hr) |
| WO (1) | WO2019115547A1 (hr) |
| ZA (1) | ZA202003472B (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019020831A1 (en) * | 2017-07-28 | 2019-01-31 | Technische Universität München | AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES |
| RS63279B1 (sr) | 2017-12-11 | 2022-06-30 | Univ Muenchen Tech | Psma ligandi za snimanje i endoradioterapiju |
| CA3128406A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universitat Munchen | Cancer diagnostic imaging agents |
| PT3917626T (pt) * | 2019-01-30 | 2023-08-23 | Technische Univ Muenchen Klinikum Rechts Der Isar | Radiomarcador de modo duplo e terapêutico de ligação a psma |
| CN114401947B (zh) | 2019-06-21 | 2024-11-29 | 省卫生服务机构 | 靶向前列腺特异性膜抗原的放射性标记化合物 |
| CN112321673B (zh) * | 2020-11-04 | 2022-09-20 | 北京市肿瘤防治研究所 | 一种前列腺特异性膜抗原靶向抑制剂及应用和探针 |
| CN113354707A (zh) * | 2021-06-07 | 2021-09-07 | 苏州思萃同位素技术研究所有限公司 | 一种针对前列腺癌的三功能诊疗一体化药物前体的合成方法及其产品 |
| WO2023173074A2 (en) * | 2022-03-10 | 2023-09-14 | The Research Foundation For The State University Of New York | Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment |
| CN115010629B (zh) * | 2022-06-07 | 2024-02-23 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用 |
| WO2025022285A2 (en) | 2023-07-21 | 2025-01-30 | Novartis Ag | Psma-targeting radioligand treatment regimen |
| US20250041461A1 (en) | 2023-07-31 | 2025-02-06 | Curium Us Llc | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof |
| WO2025147677A1 (en) * | 2024-01-05 | 2025-07-10 | Point Biopharma, Inc. | Preparation of psma-targeted radiopharmaceutical |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| ES2914593T3 (es) * | 2008-08-01 | 2022-06-14 | Univ Johns Hopkins | Agentes de unión a PSMA y usos de los mismos |
| WO2010135431A2 (en) * | 2009-05-19 | 2010-11-25 | The Regents Of The University Of California | Compositions, devices, and methods related to prostate-specific membrane antigen |
| GEP20217330B (en) * | 2013-10-18 | 2021-12-10 | Ruprecht Karls Univ Heidelberg De | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3140282B1 (en) * | 2014-05-06 | 2019-07-10 | The Johns Hopkins University | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| PT3925952T (pt) * | 2016-03-22 | 2023-12-13 | Univ Johns Hopkins | Agentes alvo de alta afinidade direcionados ao antigénio de membrana específica da próstata para endo radioterapia de cancro da próstata |
| WO2019118298A1 (en) | 2017-12-11 | 2019-06-20 | Helsinn Therapeutics (Us) Inc | Fumarate salt of (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof |
| RS63279B1 (sr) | 2017-12-11 | 2022-06-30 | Univ Muenchen Tech | Psma ligandi za snimanje i endoradioterapiju |
| TW201930265A (zh) | 2017-12-11 | 2019-08-01 | 西班牙商阿爾米雷爾有限公司 | 作為acc抑制劑的吡咯衍生物 |
-
2018
- 2018-12-11 RS RS20220527A patent/RS63279B1/sr unknown
- 2018-12-11 SI SI201831155T patent/SI4008359T1/sl unknown
- 2018-12-11 HU HUE21218180A patent/HUE069034T2/hu unknown
- 2018-12-11 US US16/765,729 patent/US11497819B2/en active Active
- 2018-12-11 EP EP18812215.4A patent/EP3723815B1/en active Active
- 2018-12-11 IL IL319022A patent/IL319022A/en unknown
- 2018-12-11 EP EP21218180.4A patent/EP4008359B1/en active Active
- 2018-12-11 CU CU2020000052A patent/CU24677B1/es unknown
- 2018-12-11 ES ES21218180T patent/ES2997266T3/es active Active
- 2018-12-11 SM SM20240439T patent/SMT202400439T1/it unknown
- 2018-12-11 CA CA3078104A patent/CA3078104A1/en active Pending
- 2018-12-11 WO PCT/EP2018/084399 patent/WO2019115547A1/en active IP Right Grant
- 2018-12-11 BR BR112020011727-7A patent/BR112020011727A2/pt unknown
- 2018-12-11 EP EP24198677.7A patent/EP4464341A3/en active Pending
- 2018-12-11 DK DK21218180.4T patent/DK4008359T3/da active
- 2018-12-11 AU AU2018382479A patent/AU2018382479B2/en active Active
- 2018-12-11 PT PT188122154T patent/PT3723815T/pt unknown
- 2018-12-11 MX MX2020005430A patent/MX2020005430A/es unknown
- 2018-12-11 SG SG11202002965WA patent/SG11202002965WA/en unknown
- 2018-12-11 SI SI201830691T patent/SI3723815T1/sl unknown
- 2018-12-11 HU HUE18812215A patent/HUE059083T2/hu unknown
- 2018-12-11 JO JOP/2020/0135A patent/JOP20200135A1/ar unknown
- 2018-12-11 NZ NZ763033A patent/NZ763033A/en unknown
- 2018-12-11 CR CR20200241A patent/CR20200241A/es unknown
- 2018-12-11 ES ES18812215T patent/ES2914832T3/es active Active
- 2018-12-11 HR HRP20220764TT patent/HRP20220764T1/hr unknown
- 2018-12-11 PL PL18812215.4T patent/PL3723815T3/pl unknown
- 2018-12-11 TN TNP/2020/000072A patent/TN2020000072A1/en unknown
- 2018-12-11 RS RS20241176A patent/RS66086B1/sr unknown
- 2018-12-11 IL IL274072A patent/IL274072B2/en unknown
- 2018-12-11 LT LTEPPCT/EP2018/084399T patent/LT3723815T/lt unknown
- 2018-12-11 UA UAA202003533A patent/UA126413C2/uk unknown
- 2018-12-11 PT PT212181804T patent/PT4008359T/pt unknown
- 2018-12-11 DK DK18812215.4T patent/DK3723815T3/da active
- 2018-12-11 FI FIEP21218180.4T patent/FI4008359T3/fi active
- 2018-12-11 CN CN202310801735.3A patent/CN116617421A/zh active Pending
- 2018-12-11 PE PE2020000552A patent/PE20210456A1/es unknown
- 2018-12-11 KR KR1020207014036A patent/KR102815791B1/ko active Active
- 2018-12-11 LT LTEP21218180.4T patent/LT4008359T/lt unknown
- 2018-12-11 IL IL313103A patent/IL313103B2/en unknown
- 2018-12-11 HR HRP20241453TT patent/HRP20241453T1/hr unknown
- 2018-12-11 CN CN201880056196.2A patent/CN111182927B/zh active Active
- 2018-12-11 JP JP2020526146A patent/JP7317375B2/ja active Active
-
2020
- 2020-06-03 EC ECSENADI202029142A patent/ECSP20029142A/es unknown
- 2020-06-10 CL CL2020001542A patent/CL2020001542A1/es unknown
- 2020-06-10 ZA ZA2020/03472A patent/ZA202003472B/en unknown
- 2020-07-13 MX MX2023005053A patent/MX2023005053A/es unknown
-
2022
- 2022-07-15 US US17/866,034 patent/US20230122957A1/en active Pending
- 2022-07-20 CY CY20221100496T patent/CY1125376T1/el unknown
-
2023
- 2023-07-11 JP JP2023113523A patent/JP7572080B2/ja active Active
-
2024
- 2024-10-03 JP JP2024173980A patent/JP2025011169A/ja active Pending
-
2025
- 2025-02-07 AU AU2025200837A patent/AU2025200837A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241453T1 (hr) | Psma ligandi za snimanje i endoradioterapiju | |
| JP2021505532A5 (hr) | ||
| AU2019365377B2 (en) | Marking precursor with squaric acid coupling | |
| RU2118325C1 (ru) | Комплексы металлов с бициклополиазамакроциклом, способ их получения и фармацевтическая композиция для лечения рака | |
| CA2225453C (en) | Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy and diagnosis | |
| JP2020528461A5 (hr) | ||
| JP2016193934A5 (hr) | ||
| US10280183B2 (en) | Therapeutic agent for treating tumors | |
| AR072488A1 (es) | Derivados heterociclicos de 1,2,4-triazol, agonistas de receptores beta 2 adrenergicos y antagonistas muscarinicos colinergicos, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de afecciones respiratorias, inflamatorias y alergicas. | |
| JP2011529919A5 (hr) | ||
| WO1997001360A9 (en) | Compounds with chelation affinity and selectivity for first transition series elements and their use in medical therapy and diagnosis | |
| MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
| KR910018346A (ko) | 킬레이트화 화합물 및 그의 용도 | |
| SE8004792L (sv) | Nya tetra- eller pentapeptider, forfaranden for framstellning av desamma och farmaceutiska kompositioner innehallande desamma | |
| MX9305181A (es) | Derivados de los acidos y tienilo o pirrolil carboxilicos procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| RU2008150377A (ru) | Новое соединение, обладающее сродством к амилоиду | |
| HRP20131103T1 (hr) | Benzimidazoli i njihovi farmaceutski pripravci | |
| JP2005511556A5 (hr) | ||
| AR069800A1 (es) | Derivados 5- aminociclilmetil - oxazolidin-2- ona | |
| AU2016289474C1 (en) | HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents | |
| NI201000049A (es) | Método para producir 2'-desoxi-5-azacitidina (decitabina) | |
| DK0909184T3 (da) | Målrettet lægemiddelindgivelse ved anvendelse af sulfonamidderivater | |
| RU2008147002A (ru) | Новые соединения, обладающие сродством к амилоиду | |
| CA2485339A1 (en) | Radiopharmaceutical formulations | |
| RS51557B (en) | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS ALFA 7 NICOTINE ACETYLHOLINE RECEPTORS |